Product Description
VL#FIA3-30 is a preparation intended for topical use, applied on the penis, for the treatment of ED. VasoLead's preparation to treat erectile dysfunction (ED), VL#FIA3-30, is composed of 2 active pharmaceutical ingredients, both act as vasodilators via different mechanisms. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02496845)
Mechanisms of Action: ADRA1 Antagonist
Novel Mechanism: Yes
Modality: Unknown
Route of Administration: Transdermal
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: VasoLead (2012)
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Erectile Dysfunction
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| VL#FIA3-30 #002 | P2 |
Unknown status |
Erectile Dysfunction |
2015-11-01 |
2019-03-20 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|